Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug;113(8):1219-1231.
doi: 10.1007/s00392-024-02381-x. Epub 2024 Jan 24.

Risk and effect modifiers for poor glycemic control among the chinese diabetic adults on statin therapy: the kailuan study

Zhaogui Wu #  1 , Shuohua Chen #  2 , Xixi Tao  1 , Hangkuan Liu  1 , Pengfei Sun  1 , Arthur Mark Richards  3   4 , Huay Cheem Tan  4   5 , Ying Yu  6 , Qing Yang  7 , Shouling Wu  8 , Xin Zhou  9
Affiliations

Risk and effect modifiers for poor glycemic control among the chinese diabetic adults on statin therapy: the kailuan study

Zhaogui Wu et al. Clin Res Cardiol. 2024 Aug.

Abstract

Background: Limited studies have investigated the association between statin therapy and poor glycemic control, especially in the Chinese diabetic population.

Methods: Two prospective diabetes cohorts were drawn from the Kailuan Cohort. In Cohort 1, linear regression models were used to evaluate the association between statin therapy and glycated hemoglobin (HbA1c) level change. In Cohort 2, new user design and conditional logistic models were used to assess associations between statin initiation and poor glycemic control which was a composite outcome comprised of hypoglycemic agent escalation and new-onset hyperglycemia.

Results: Among 11,755 diabetic patients with medication information, 1400 statin users and 1767 statin nonusers with repeated HbA1c measurements were included in Cohort 1 (mean age: 64.6 ± 10.0 years). After a median follow-up of 3.02 (1.44, 5.00) years, statin therapy was associated with higher HbA1c levels (β: 0.20%; 95%CI: 0.05% to 0.34%). In Cohort 2, 1319 pairs of matched cases/controls were included (mean age: 61.6 ± 9.75 years). After a median follow-up of 4.87 (2.51, 8.42) years, poor glycemic control occurred in 43.0% of statin new users and 31.8% of statin nonusers (OR: 1.69; 95% CI: 1.32 to 2.17; P < 0.001). The statin-associated poor glycemic control risk was significantly higher among patients with lower body mass index (Pint = 0.089). Furthermore, a nonlinear association was observed between statin therapy duration and poor glycemic control (P = 0.003).

Conclusions: Among Chinese diabetic adults, statin therapy was associated with a higher level of HbA1c, and a higher risk of hypoglycemic agent escalation and new-onset hyperglycemia, especially among those who had lower body mass index levels and longer statin therapy duration.

Keywords: Body mass index; Glycemic control; Nested case-control study; New user design; Statin therapy; Statin therapy duration.

PubMed Disclaimer

References

    1. Magliano DJ, Boyko EJ, committee IDFDAtes (2021) IDF Diabetes Atlas. In: Idf diabetes atlas. International Diabetes Federation © International Diabetes Federation, Brussels
    1. Wang L, Peng W, Zhao Z, Zhang M, Shi Z, Song Z, Zhang X, Li C, Huang Z, Sun X et al (2021) Prevalence and treatment of diabetes in China, 2013–2018. JAMA 326:2498–2506. https://doi.org/10.1001/jama.2021.22208 - DOI - PubMed - PMC
    1. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE et al (2019) 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 139:e1046–e1081. https://doi.org/10.1161/cir.0000000000000624 - DOI - PubMed
    1. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA et al (2020) 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41:111–188. https://doi.org/10.1093/eurheartj/ehz455 - DOI - PubMed
    1. Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Shin EK (2010) Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. J Am Coll Cardiol 55:1209–1216. https://doi.org/10.1016/j.jacc.2009.10.053 - DOI - PubMed - PMC

MeSH terms

LinkOut - more resources